Emyria Limited (ASX:EMD)

Market Cap	33.88M +146.3%
Revenue (ttm)	2.29M +29.3%
Net Income	-4.55M
EPS	-0.01
Shares Out	806.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	795,986
Open	0.0420
Previous Close	0.0410
Day's Range	0.0410 - 0.0420
52-Week Range	0.0230 - 0.0780
Beta	0.04
Analysts	Buy
Price Target	0.18 (+328.57%)
Earnings Date	Aug 27, 2026

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnersh...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In fiscal year 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.